Skip to main content
OpenTrials
Completed

NCT Number: NCT07703215

NPQ Plus Supplementation for Skin Health and Antioxidant Status

This study evaluated the effects of NPQ Plus supplementation on skin health, antioxidant status, fatigue, and self-perceived well-being in healthy adults with skin concerns. NPQ Plus is a multi-component nutraceutical formulation containing polyphenols (Oligonol®), nicotinamide mononucleotide (NMN; RevAge®), pyrroloquinoline quinone (PQQ; PureQQ®), coenzyme Q10 (CoQ10), and a trace mineral complex (Ioniplex), which are known to possess antioxidant and cellular protective properties.

This was a single-arm, open-label, prospective interventional study involving 55 participants. Subjects consumed one sachet of NPQ Plus daily for 12 weeks. Assessments were performed at baseline and at Weeks 4, 8, and 12. Skin health was evaluated using the Patient-Oriented Eczema Measure (POEM), visual analogue scale (VAS), and objective skin biophysical measurements including skin elasticity, hydration, transepidermal water loss (TEWL), pigmentation, inflammation, and sebum secretion. Antioxidant status was assessed by measuring total antioxidant capacity (TAOC), malondialdehyde (MDA), 3-nitrotyrosine (3-NT), and 8-hydroxy-2'-deoxyguanosine (8-OHdG). Fatigue symptoms and self-perceived improvements in skin health, sleep quality, and overall well-being were also evaluated.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Eczema Antioxidant Capacity Atopic Dermatitis Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dermatitis Dermatitis, Atopic Dyssomnias Fatigue Fatigue Symptom Genetic Diseases, Inborn Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Mental Disorders Nervous System Diseases Oxidative Stress Pathological Conditions, Signs and Symptoms Signs and Symptoms Skin Diseases Skin Diseases, Eczematous Skin Diseases, Genetic Skin Health Skin and Connective Tissue Diseases Sleep Disorders, Intrinsic Sleep Initiation and Maintenance Disorders Sleep Quality Sleep Wake Disorders

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

UCSI University

Cheras, Kuala Lumpur, 56000, Malaysia

About this study

Skin aging is influenced by intrinsic aging processes and environmental stressors, including ultraviolet radiation, pollution, and oxidative stress. These factors contribute to impaired skin barrier function, reduced hydration and elasticity, inflammation, pigmentation changes, and increased oxidative damage to lipids, proteins, and DNA. Nutraceutical supplementation containing antioxidant and mitochondrial-supporting bioactive compounds has emerged as a potential strategy to mitigate these changes by enhancing endogenous antioxidant defenses and supporting cellular repair mechanisms.

NPQ Plus is a multi-component nutritional supplement comprising polyphenols (Oligonol®), nicotinamide mononucleotide (NMN; RevAge®), pyrroloquinoline quinone (PQQ; PureQQ®), coenzyme Q10 (CoQ10), and a trace mineral complex (Ioniplex). These ingredients have been reported to possess antioxidant, anti-inflammatory, and mitochondrial-supportive properties that may improve skin condition, reduce oxidative stress, and alleviate fatigue.

This completed study employed a single-arm, open-label, prospective interventional design. Fifty-five healthy adults with skin concerns were enrolled and instructed to consume one sachet of NPQ Plus daily for 12 weeks. Clinical assessments were conducted at baseline and after 4, 8, and 12 weeks of supplementation.

The primary evaluations included objective skin biophysical measurements using the Multiprobe Adapter (MPA) system, consisting of skin elasticity (Cutometer®), skin hydration (Corneometer®), transepidermal water loss (Tewameter®), skin inflammation and pigmentation (Mexameter®), and sebum secretion (Sebumeter®). Patient-reported skin outcomes were assessed using the Patient-Oriented Eczema Measure (POEM), visual analogue scale (VAS), and self-perceived improvements in skin health.

Systemic antioxidant status and oxidative damage were evaluated using saliva biomarkers, including total antioxidant capacity (TAOC), malondialdehyde (MDA), 3-nitrotyrosine (3-NT), and 8-hydroxy-2'-deoxyguanosine (8-OHdG). Fatigue was assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale, while participants also reported changes in sleep quality and overall well-being.

The study aimed to characterize longitudinal changes following NPQ Plus supplementation across multiple domains, including skin health, antioxidant status, fatigue symptoms, and participant-reported outcomes, over the 12-week intervention period.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Experiencing at least one skin concern (e.g., itchiness, dryness, roughness, flaking, or skin cracking) within the previous 3 months.
  • Willing and able to consume one sachet of NPQ Plus daily for 12 weeks.
  • Willing to attend all scheduled study visits and assessments.
  • Able to understand the study procedures and provide written informed consent.

Exclusion criteria

  • Consumption of dietary supplements intended to improve skin health within the previous 3 months.
  • Pregnant or breastfeeding women.
  • Known allergy or hypersensitivity to any ingredient in NPQ Plus.
  • Presence of any medical condition or concurrent medication that, in the opinion of the investigator, could interfere with study participation or outcome assessments.
  • Participation in another clinical study within the previous 3 months.
  • Unable or unwilling to comply with the study protocol.

Treatment and study plan

NPQ Plus

Dietary Supplement

NPQ Plus is a dietary supplement containing Oligonol® (polyphenols), nicotinamide mononucleotide (NMN; RevAge®), pyrroloquinoline quinone (PQQ; PureQQ®), coenzyme Q10 (CoQ10), and a trace mineral complex (Ioniplex). Participants consumed one sachet orally once daily for 12 weeks.

Primary outcomes

  1. Skin Elasticity

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Skin elasticity was measured using the Cutometer® (MPA580, Courage & Khazaka, Germany). Measurements were obtained from the left cheek, right inner forearm, and dorsal neck under standardized environmental conditions. Three consecutive readings were recorded at each site and the mean value was used for analysis. Higher values indicate greater skin elasticity.

  2. Skin Hydration

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Skin hydration was assessed using the Corneometer® CM825. Measurements were obtained from the left cheek, right inner forearm, and dorsal neck. Three readings were averaged for each anatomical site. Higher values indicate greater skin hydration.

  3. Transepidermal Water Loss (TEWL)

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Skin barrier function was evaluated by measuring transepidermal water loss using the Tewameter® TM300. Measurements were performed under standardized environmental conditions. Lower values indicate improved skin barrier integrity.

  4. Skin Inflammation

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Skin inflammation was assessed using the erythema index measured by the Mexameter® MX18. Lower erythema values indicate reduced skin inflammation.

  5. Skin Pigmentation

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Skin pigmentation was evaluated using the melanin index measured by the Mexameter® MX18. Changes in melanin index were assessed throughout the intervention.

  6. Sebum Secretion

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Sebum secretion was measured using the Sebumeter® SM815. Three measurements were obtained and averaged for each assessment site. Higher values indicate greater sebum production.

  7. Patient-Oriented Eczema Measure (POEM)

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Skin symptoms were assessed using the Patient-Oriented Eczema Measure (POEM), a validated patient-reported questionnaire evaluating eczema severity over the previous week. Lower scores indicate less severe symptoms.

Secondary outcomes

  1. Total Antioxidant Capacity (TAOC)

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Total antioxidant capacity was determined from saliva samples using a ferric reducing antioxidant capacity (FRAC) assay. Higher values indicate greater antioxidant capacity.

  2. Malondialdehyde (MDA)

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Lipid oxidative damage was assessed by measuring salivary malondialdehyde (MDA). Lower concentrations indicate reduced lipid peroxidation.

  3. 3-Nitrotyrosine (3-NT)

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Protein oxidative damage was assessed by measuring salivary 3-nitrotyrosine (3-NT), a biomarker of protein nitration. Lower concentrations indicate reduced protein oxidative damage.

  4. 8-Hydroxy-2'-deoxyguanosine (8-OHdG)

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Oxidative DNA damage was assessed by measuring salivary 8-hydroxy-2'-deoxyguanosine (8-OHdG). Lower concentrations indicate reduced oxidative DNA damage.

  5. Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Fatigue severity was assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) questionnaire. Lower scores indicate lower fatigue severity.

  6. Self-perceived Outcomes

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Participants rated their overall skin health, skin itchiness and sleep quality using a visual analogue scale (VAS). Ten indicate the best possible outcome, and zero indicate the worst possible outcome.

Sponsors and collaborators

Lead sponsor

N REMEDIER (M) SDN BHD

Industry

Collaborators

  • JScience Consultancy PLT
  • UCSI University

Registry information

Official study title

Effects of NPQ Plus Supplementation on Skin Health, Antioxidant Status, Fatigue and Self-Perceived Well-being: A Single-Arm Prospective Interventional Study

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jul 14, 2026
Registry last updated
Jul 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.